Amy Goodrich, RN, MSN, CRNP-AC, is a nurse practitioner in the Hematologic Malignancies Program at The Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland where she manages patients with various types of hematologic malignancies, concentrating on the lymphomas. Goodrich also oversees the Cancer Center’s research nurses and is very involved in research operations. She has presented extensively on hematologic malignancies, new agents, symptom management, and a variety of topics important to oncology nursing.
She earned her undergraduate nursing degree from the University of Pittsburgh and earned her master’s degree from The Johns Hopkins University.
Dr. Hill is the Director of the Lymphoid Malignancies Program at the Cleveland Clinic Taussig Cancer Institute. He received his undergraduate degree from Dartmouth College and earned his Ph.D. in genetics through work done at Cold Spring Harbor Laboratory. He received his medical degree from the University of Chicago Pritzker School of Medicine where he also completed his residency in Internal Medicine. He conducted his hematology/oncology fellowship at the Cleveland Clinic. His clinical and research focus is in chronic lymphocytic leukemia (CLL) and lymphoma. He is the principal investigator of multiple on-going clinical trials of new cancer treatments including novel cellular therapies. He serves as the Chairman of the Pharmacy & Therapeutics (P&T) Committee within the Department of Hematology and Medical Oncology, co-director of the Lymphoid Malignancies Center of Excellence and serves on the editorial board of several peer reviewed journals. He is Associate Professor of Medicine of the Cleveland Clinic Lerner College of Medicine is an active member of the Case Comprehensive Cancer Center, American Society of Hematology (ASH), National Cancer Institute (NCI) cooperative groups in leukemia and lymphoma, the Center for International Blood and Marrow Transplant Research (CIBMTR) as well as a committee member of the National Comprehensive Cancer Network (NCCN).
Ben Kosewski, MS, MBA, is the executive director of cancer services at the Western Maryland Health System (WMHS) Schwab Family Cancer Center, which serves patients in the tri-state region of Maryland, Pennsylvania, and West Virginia. Mr. Kosewski is integral in the development of the WMHS Center for Breast Care, a program that earned accreditation by the National Accreditation Program for Breast Centers in March 2018. He was also recently appointed to the Maryland State Council on Cancer Control. Prior to his role, Mr. Kosewski worked as a program and services manager in the cancer service line for a community hospital in Bellevue, Washington. He holds a Master of Business Administration and a Master of Science in Genetic Counseling.
Dr. Pagel is a 2019 Seattle Met Top Doctor Award winner. Dr. Pagel is an international hematology expert with a world-class reputation for research and excellence in patient care. He is dedicated to individualized patient care that is based on mutual respect and trust. He is incredibly excited to be a part of the Swedish Cancer Institute. Dr. Pagel feels the work being done here is life-changing for patients and will deliver new advancements in cancer treatment for patients in the Pacific Northwest and beyond. Prior to joining Swedish, Dr. Pagel spent more than a decade as an associate member of the Clinical Research Division at the Fred Hutchinson Cancer Research Center and associate professor in the Medical Oncology Division at the University of Washington.
Timothy S. Pardee, MD, PhD, is a practicing hematologist and medical oncologist with a clinical focus on acute and chronic leukemias; associate professor of internal medicine, section on hematology/oncology and cancer biology; director of leukemia translational research; and co-leader of the hematology disease-oriented group at Wake Forest University Medical School. In addition to his clinical duties, Dr. Pardee heads an NCI-funded research program focused on the role of cellular metabolism in leukemia cell survival and resistance to therapy as well as novel therapeutics. He is active in clinical trials with a specific interest in the development of CPI-613, a first-in-class mitochondrial metabolism inhibitor. He conducted and published the first-in-human phase I clinical trial using CPI-613—building on clinical and preclinical work—he then completed a phase I trial of this agent in combination with high-dose cytarabine and mitoxantrone for patients with relapsed or refractory acute myeloid leukemia.
Dr. Pardee is an active member of the Leukemia Correlative Science Committee for the Alliance for Clinical Trials in Oncology, and a recipient of numerous teaching and clinical awards including recognition in the “Best Doctors in America List” (2015-2016, 2017-2018); a 2015 Master Teacher Award from the house staff of the Department of Medicine at Wake Forest University; and the 2016 Best Teacher and Role Model Award from the third year medical school class. He was awarded a KO8 in 2012 for his work in AML metabolism and novel therapeutics, and in 2016, an R01. He continues to work clinically and preclinically to bring better treatments to patients suffering from acute and chronic leukemias.
Jolynn K. Sessions, PharmD, BCOP, is the oncology clinical pharmacist for Mission Health System in Asheville, North Carolina, and associate professor of clinical education at the UNC Eshelman School of Pharmacy’s Asheville satellite campus. Previously, Dr. Sessions served as oncology clinical coordinator, oncology PGY2 residency director, and clinical pharmacist at Emory Hospital/Winship Cancer Institute in Atlanta. Her first job out of specialty residency was at Grady Health System in Atlanta where she developed the role of an oncology clinical pharmacist and established both clinical and distributive services.
She is a member of the Hematology Oncology Pharmacy Association and has served as treasurer, board of directors, chair, and vice chair of the Continuing Education Committee. She is also a member of the North Carolina Oncology Pharmacists Association.
Dr. Sessions is a graduate of the University of Florida College of Pharmacy. She completed a PGY1 residency at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and a PGY2 residency at University of Texas MD Anderson Cancer Center in Houston.
Jennifer Wang, LCSW, is an oncology social worker at Advocate Lutheran General Hospital, where she works with patients and families at the Cancer Survivorship Center. Ms. Wang meets with patients for individual and family counseling, facilitating support groups as well as linking patients with community resources. She has a background in private practice, counseling patients with a relational framework.
Dr. Koffman is a well-known doctor, educator, and clinical professor-turned-patient who has dedicated himself to teaching and helping the CLL community since his own CLL diagnosis in 2005. Dr. Koffman believes that his dual roles as a retired physician and patient give him a unique understanding that allows him to provide clear explanations of complex issues, advocate for his fellow patients, and inform his fellow healthcare providers. Besides his medical degree, Dr. Koffman has a master’ degree in medical education. He is a retired family doctor and clinical professor at the Keck School of Medicine.
Dr. Koffman co-founded and serves as the chief medical officer and executive vice president of the nonprofit, CLL Society Inc., and he writes a widely followed blog. Dr. Koffman has shared online and across the world his battle with his leukemia, including a failed bone marrow transplant and successes with two Phase 1 trials, including CAR T-cell therapy.
This project is supported by Pharmacyclics and Janssen Oncology.
